Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Simpson EL, Eichenfield LF, Papp KA, Forman SB, Hebert AA, Gonzalez ME, Gooderham MJ, Hong HC, Prajapati VH, Guttman-Yassky E, Silverberg JI, Seal MS, Krupa D, Almaraz E, Hanna D, Burnett P, Snyder S, Chu DH, Higham RC, Berk DR. Simpson EL, et al. Among authors: chu dh. Dermatitis. 2025 Jan 10. doi: 10.1089/derm.2024.0418. Online ahead of print. Dermatitis. 2025. PMID: 39792455
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, Gooderham M, Gonzalez ME, Hebert AA, Kircik LH, Lomaga M, Moore A, Papp KA, Prajapati VH, Hanna D, Snyder S, Krupa D, Burnett P, Almaraz E, Higham RC, Chu DH, Berk DR. Simpson EL, et al. Among authors: chu dh. JAMA Dermatol. 2024 Nov 1;160(11):1161-1170. doi: 10.1001/jamadermatol.2024.3121. JAMA Dermatol. 2024. PMID: 39292443 Free PMC article. Clinical Trial.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Blauvelt A, Draelos ZD, Stein Gold L, Alonso-Llamazares J, Bhatia N, DuBois J, Forman SB, Gooderham M, Green L, Guenthner ST, Hebert AA, Lain E, Moore AY, Papp KA, Zirwas M, Kato S, Snyder S, Krupa D, Burnett P, Berk DR, Chu DH. Blauvelt A, et al. Among authors: chu dh. J Am Acad Dermatol. 2024 May;90(5):986-993. doi: 10.1016/j.jaad.2023.12.065. Epub 2024 Jan 20. J Am Acad Dermatol. 2024. PMID: 38253129 Free article. Clinical Trial.
Mitigating antimicrobial resistance (AMR) using implementation research: a development funder's approach.
Khurana MP, Essack S, Zoubiane G, Sreenivasan N, Cordoba GC, Westwood E, Dalsgaard A, Mdegela RH, Mpundu M, Scotini R, Matondo AB, Mzula A, Chanishvili N, Gogebashvili D, Beruashvili M, Tsereteli M, Sooronbaev T, Kjærgaard J, Bloch J, Isaeva E, Mainda G, Muuka G, Mudenda NB, Goma FY, Chu DH, Chanda D, Chirwa U, Yamba K, Kapolowe K, Fwoloshi S, Mwenge L, Skov R. Khurana MP, et al. Among authors: chu dh. JAC Antimicrob Resist. 2023 Mar 27;5(2):dlad031. doi: 10.1093/jacamr/dlad031. eCollection 2023 Apr. JAC Antimicrob Resist. 2023. PMID: 36994233 Free PMC article. Review.
55 results